

Phase I Trial: 323476

Submission date 10/09/2024	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 13/09/2024	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 13/09/2024	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Scientific, Principal investigator

Contact name

Prof Amanda Adler

Contact details

University of Oxford, Diabetes Trial Unit
Oxford
United Kingdom
OX3 7LJ

-
enquiries@rdm.ox.ac.uk

Type(s)

Public

Contact name

Dr Information Team

Contact details

117 Charterhouse Street
London
United Kingdom
EC1M 6AA

-
info@sava.health

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

323476

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 323476, CPMS 59146

Study information

Scientific Title

The full scientific title will be published within 30 months after the end of the trial

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 22/03/2024, London - Dulwich Research Ethics Committee (2nd Floor, 2 Redman Place, London, E20 1JO, United Kingdom; 0207 104 8290; dulwich.rec@hra.nhs.uk), ref: 24/LO/0134

Study design

Multi-site trial with 50 participants

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

01/06/2025

Eligibility**Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Other

Healthy volunteers allowed

No

Age group

Not Specified

Sex

All

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

20/09/2024

Date of final enrolment

01/04/2025

Locations

Countries of recruitment

United Kingdom

England

Study participating centre**Addenbrooke's Hospital Laboratory**

Addenbrookes Hospital

Hills Road

Cambridge

United Kingdom

CB2 0QQ

Sponsor information

Organisation

SAVA Technologies Ltd.

Funder(s)

Funder type

Industry

Funder Name

SAVA Technologies Ltd.

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes